CME Presentations

Urothelial Carcinoma



  • Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.

    Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 175 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.

    A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
  • Scott T. Tagawa, MD, MS

    Scott T. Tagawa, MD, MS

    Scott T. Tagawa, MD, MS

    Associate Professor of Clinical Medicine & Urology

    Scott T. Tagawa, MD, MS, is the Richard A. Stratton Associate Professor in Hematology and Oncology and associate professor of clinical urology and medicine at Weill Cornell Medical College (WCMC), Cornell University, as well as an associate attending physician at New York-Presbyterian Hospital. He leads clinical trials prostate, bladder, and kidney cancer as well as the prevention and treatment of thrombosis with cancer. Dr Tagawa specializes in prostate cancer drug development, with an interest in prostate-specific membrane antigen theranostics. He is the WCMC principal investigator for the Alliance for Clinical Trials in Oncology and is a member of the American Society of Clinical Oncology’s Clinical Practice Guidelines Committee.
  • Elizabeth Plimack, MD, MS

    Elizabeth Plimack, MD, MS

    Elizabeth Plimack, MD, MS

    Chief, Division of Genitourinary Medical Oncology

CME Information

Global Logo PQH Logo
When Initial Therapy Fails - What's Next in Urothelial Carcinoma
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Large Urology Group Practice Association (LUGPA).


This activity is supported by an educational grant from Gilead Sciences, Inc.


This activity was released on February 25, 2022 and is valid until February 25, 2023. Requests for credit must be made no later than February 25, 2023.


The primary target audiences for the HCP activity are medical oncologists, urologists, pharmacists, nurse practitioners, physician assistants, nurses, and other HCPs managing patients with UC.


A deeper understanding of the pathophysiology of urothelial carcinoma (UC) has revealed targetable biomarkers, while recent advancements in precision medicine, such as antibody-drug conjugates, promise to improve long-term survival in patients with advanced disease. Clinicians can help facilitate the integration of these therapies into practice in effort to optimize outcomes for patients who do not respond to initial therapy.

Join a panel of expert oncologists and urologists for an in-depth discussion of evidence-based approaches to managing advanced UC, including the detection of disease recurrence, treatment selection for metastatic disease refractory to chemotherapy and/or immunotherapy, and the importance of multidisciplinary care. Panelists will review the data on emerging therapies that have shown promise in difficult-to-treat patient populations with advanced UC and describe real-world patient experiences and strategies to improve care.

Do you have patients who could benefit from related education on the management of UC and associated side effects? Direct your patients to to access the related patient-education activity, “Are There Treatment Options for Advanced Urothelial Cancer?”


After completing this activity, the participant should be better able to:
  • Review characteristics that guide treatment selection in the second-line setting and beyond for patients with advanced UC
  • Evaluate clinical-trial efficacy and safety data for emerging agents that target disease progression in patients with advanced UC
  • Discuss multidisciplinary team roles/responsibilities for efficient transition of care


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Fox Chase Center
Consulting Fee: Astellas, AstraZeneca, Aveo, Exelexis, BMS, Calithera, Janssen, Merck, Natera, Pfizer, Regeneron, Seattle Genetics
Contracted Research: Grants for clinical research: Astellas, BMS, Genentech, Merck
Neal Shore, MD
Medical Director, CPI, Carolina Urologic Research Center Chief Medical Officer, Surgical Oncology and Urology, Genesis Care US
Consulting Fee (e.g., Advisory Board): Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Boston Scientific, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Propella, PreView, Sanofi Genzyme ,Speciality Networks, Sesen Bio, Tolmar, Urogen Speakers' Bureau: Astellas, AstraZeneca, Bayer, Clovis Oncology, Foundation Medicine, Janssen, Merck, Pfizer, Guardant Health
Scott Tagawa, MD
Richard A. Stratton Associate Professor in Hematology and Oncology, Associate Professor of Clinical Medicine & Urology at Weill Cornell Medicine, Associate Attending Physician at NewYork- Presbyterian – Weill Cornell Medical Center
Consulting Fee: Sanofi, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth Diagnostics, AIkido Pharma, Telix Pharma, Convergent Therapeutics, EMD Serono

Contracted Research: Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyopharm, Endocyte, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma

Royalty: Gilead
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship
Rhys Williams, RN, MSN, FNP Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Tariqua Ackbarali Nothing to disclose
Caroline Laurendeau Nothing to disclose
John Lanci-Patient Honoraria: Johnson and Johnson/Janssen Pharmaceutical
Karl Pritchard-Patient Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive or UroCareLive at 877-394-1306 or at or